Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Skye Bioscience, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.942 -- 00:00:04.386 Hello, and thank you all for participating in today's call. 00:00:04.386 -- 00:00:10.293 Joining me today is Puneet Dhillon, Sky's President and CEO, Chris Twitty, CSO, 00:00:10.293 -- 00:00:14.158 and Caitlin Arsenault, Sky's CFO. 00:00:14.158 -- 00:00:18.043 Before we begin, I'd like to caution that comments made during this conference call will 00:00:18.043 -- 00:00:21.547 contain forward-looking statements under the safe harbor provisions of the U.S. 00:00:21.547 -- 00:00:27.154 Private Securities Litigation Reform Act of 1995, including statements about Sky's expectations 00:00:27.154 -- 00:00:31.977 regarding its development activities, timelines, and milestones. 00:00:32.515 -- 00:00:36.181 forward-looking statements are subject to risks and uncertainties that could cause actual 00:00:36.181 -- 00:00:40.608 results to differ materially and adversely, and reported results should not be considered 00:00:40.608 -- 00:00:43.513 as an indication of future performance. 00:00:43.513 -- 00:00:47.059 These forward-looking statements speak only as of today's date, and the company undertakes 00:00:47.059 -- 00:00:50.164 no obligation to revise or update any statements made today. 00:00:50.164 -- 00:00:54.050 I encourage you to review all the company's filings with the Securities and Exchange 00:00:54.050 -- 00:00:57.276 Commission concerning these and other matters. 00:00:57.276 -- 00:01:01.019 I'll now turn the call over to Puneet Gillan. 00:01:01.287 -- 00:01:03.329 Good afternoon and thank you for joining us. 00:01:03.329 -- 00:01:09.095 I'm here with members of our management team to review Sky's first quarter 2025 performance. 00:01:09.095 -- 00:01:13.279 I'll briefly recap our key upcoming clinical milestones and highlight our op...